3 results match your criteria: "University of Southern California Norris Comprehensive Cancer Center. Electronic address: diquinn@usc.edu.[Affiliation]"
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape.
Ann Oncol
March 2022
Section of Genitourinary Medical Oncology, University of Southern California Norris Comprehensive Cancer Center. Electronic address:
Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
Urol Oncol
May 2015
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
Background: The approval of sipuleucel-T in conjunction with data from other immunotherapeutic trials for prostate cancer and other solid tumors demonstrates the potential of harnessing the patients' immune system for long-term survival. Thus, a range of therapeutic approaches are under evaluation. This review describes the rationale for immunotherapy for prostate cancer, summarizes the approaches under evaluation, and discusses sequencing options for immunotherapy in the current treatment paradigm.
View Article and Find Full Text PDFSpeeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
Ann Oncol
February 2013
Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA. Electronic address: